Pharma companies file 15% of patents in India: Report

Around 15 percent of the total 1.3 lakh patents filed in India from 2013 to 2015 was contributed by the pharmaceutical industry, according to report by Clarivate Analytics

Largely known for generic drugs, the Indian pharmaceutical industry  has started moving up the value chain as it invests more money in research to develop new drugs and reformulate the existing ones.
Around 15 percent of the total 1.3 lakh patents filed in India from 2013 to 2015 was contributed by the pharmaceutical industry, according to a report by Clarivate Analytics
The report titled ‘India Innovation: Trends’ was compiled using Thomson Innovation, Derwent World Patents Index (DWPI), Derwent Patent Citations Index (PCI) and Thomson Data Analyzer.
Here are some key highlights from the report:
1) Indian headquartered pharmaceutical companies top the list of key assignees with India priority patents in the pharmaceutical sector. Nearly 135 unique molecules from more than 45 Indian pharmaceutical companies are undergoing various phases of clinical trials for key therapy areas such as cancer, diabetes, allergic rhinitis, osteoarthritis, among others. Around 30 percent of those molecules are in phase-3 or late stage clinical trials.
2) The innovation in the pharmaceutical category is focused mainly on drug combinations (26 percent), anti-inflammatory drugs (23 percent), natural products made of plant extracts (19 percent), anti-bacterial drugs (17 percent) and anti-cancer drugs (15 percent). Focus on natural products for pharmaceutical use is in line with the historical roots and popularity of Ayurveda in India.
3) The top patent filers in pharmaceuticals include Cadila Healthcare, Council of Scientific and Industrial Research (CSIR), Dr.Reddy's, Wockhardt, Amity University, Cipla, Sun Pharma, Aurobindo and Lupin.
4) Top companies on an average have shown an increase in their aggregated R&D expenditure from 6 percent of sales in 2011 to more than 9 percent in 2016.
5) Indian companies have signed 55 deals with various research institutes and other pharmaceutical companies including multinationals. Out of 55 deals, 14 deals are in context of drug development services, 11 deals are M&A deals, 9 deals are in context of drug-manufacturing supply, and 8 deals were for drug development and commercialisation.
In terms of indications, 12 of these 50 active deals are focusing on chronic diseases such as epilepsy, diabetes, dermatology and inflammation, six deals are focusing on developing drugs for antibacterial and antiviral treatments across multiple infections and five deals are focusing on oncology.
Most of the deals in drug development are early stage partnerships.

Source:http://www.moneycontrol.com/news/trends/health-trends/india-pharma-companies-lead-in-patent-filing-report-2272395.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more